Unraveling Parkinson’s disease: from dopaminergic dysfunction to novel therapeutic targets

Parkinson’s disease (PD) is a neurodegenerative disorder influenced by multiple factors and primarily defined by the gradual loss of dopaminergic neurons within the substantia nigra pars compacta. This pathological process fundamentally reduces available dopamine levels and produces core motor symptoms that include bradykinesia, resting tremor, rigidity, postural instability, and a generalized loss of balance. However, the pathology of PD appears to include far more than nigrostriatal function, as it is increasingly recognized that PD extends across the central and peripheral nervous systems through many different neurotransmitter systems/neurotransmitters, neuroinflammation, mitochondrial dysfunction, genetic mutations, abnormal protein aggregation (particularly of α-synuclein), and other factors. Thus, the complexities of PD are suggestive of more of a syndromic process rather than a single disease process with varied pathogenetic pathways that also result in varied clinical presentations. Traditionally, treatment options for PD have primarily focused on dopaminergic treatment strategies to manage the progressive symptoms, which include the lifestyle impact of diminished dopamine levels. This regimen primarily includes levodopa in addition to dopamine agonist options and an array of adjunctive therapies. While these early treatments are completely life-altering and provide considerable improvement for the first several years, their benefit eventually wanes, and they fundamentally simply do not alter disease progression. Recently, there has been a concerted effort to identify treatment options that are not simply a dopaminergic replacement treatment but can alter some aspects of the disease, including several novel approaches investigating mitochondrial health, neuroinflammation, autophagy, α-synuclein aggregation, and genetic regulation in both preclinical and early clinical studies. This review takes a critical look at the classic view of PD occurring as a result of dopaminergic dysfunction, extends into modern concepts that include abnormalities at the cellular and molecular levels, and describes new treatment strategies that fundamentally reflect the multifactorial nature of PD. However, its central aim is to direct the audience to interventions that not only relieve symptoms but also hold the promise to stop or reverse the disease, ultimately offering renewed hope to patients and physicians alike.

Maiti P, Manna J, Dunbar GL. Current understanding of the molecular mechanisms in Parkinson’s disease: Targets for potential treatments. Transl Neurodegener 2017;6:28. DOI: https://doi.org/10.1186/s40035-017-0099-z

Ramesh S, Arachchige ASPM. Depletion of dopamine in Parkinson’s disease and relevant therapeutic options: a review of the literature. AIMS Neurosci 2023;10:200-31. DOI: https://doi.org/10.3934/Neuroscience.2023017

Schulz-Schaeffer WJ. The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia. Acta Neuropathol 2010;120:131-43. DOI: https://doi.org/10.1007/s00401-010-0711-0

Shulman JM, De Jager PL, Feany MB. Parkinson’s disease: genetics and pathogenesis. Annu Rev Pathol 2011;6:193-222. DOI: https://doi.org/10.1146/annurev-pathol-011110-130242

Burré J. The Synaptic function of α-synuclein. J Parkinsons Dis 2015;5:699-713. DOI: https://doi.org/10.3233/JPD-150642

Lind-Holm Mogensen F, Seibler P, et al. Microglial dynamics and neuroinflammation in prodromal and early Parkinson’s disease. J Neuroinflammation 2025;22:136. DOI: https://doi.org/10.1186/s12974-025-03462-y

Wang Q, Liu Y, Zhou J. Neuroinflammation in Parkinson’s disease and its potential as therapeutic target. Transl Neurodegener 2015;4:19. DOI: https://doi.org/10.1186/s40035-015-0042-0

Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson’s disease. Lancet Neurol 2021;20:385-97. DOI: https://doi.org/10.1016/S1474-4422(21)00030-2

Corvol JC, Mariani LL. Therapeutic and pharmacologic perspectives in Parkinson’s disease. Rev Prat 2018;68:515-9. [Article in French].

Tanner CM, Goldman SM. Epidemiology of Parkinson’s disease. Neurol Clin 1996;14:317-35. DOI: https://doi.org/10.1016/S0733-8619(05)70259-0

Stefanis L. α-Synuclein in Parkinson’s disease. Cold Spring Harb Perspect Med 2012;2:a009399. DOI: https://doi.org/10.1101/cshperspect.a009399

Isik S, Yeman Kiyak B, Akbayir R, et al. Microglia mediated neuroinflammation in Parkinson’s disease. Cells 2023;12:1012. DOI: https://doi.org/10.3390/cells12071012

Sy MAC, Fernandez HH. Pharmacological treatment of early motor manifestations of Parkinson disease (PD). Neurotherapeutics 2020;17:1331-8. DOI: https://doi.org/10.1007/s13311-020-00924-4

Williams NR, Foote KD, Okun MS. Subthalamic nucleus versus globus pallidus internus deep brain stimulation: translating the rematch into clinical practice. Mov Disord Clin Pract 2014;1:24-35. DOI: https://doi.org/10.1002/mdc3.12004

Postuma RB, Aarsland D, Barone P, et al. Identifying prodromal Parkinson’s disease: pre-motor disorders in Parkinson’s disease. Mov Disord 2012;27:617-26. DOI: https://doi.org/10.1002/mds.24996

Xiao B, Tan EK. Prasinezumab slows motor progression in Parkinsons disease: beyond the clinical data. NPJ Parkinsons Dis 2025;11:31. DOI: https://doi.org/10.1038/s41531-025-00886-4

Saarma M, Sariola H. Other neurotrophic factors: glial cell line-derived neurotrophic factor (GDNF). Microsc Res Tech 1999;45:292-302. DOI: https://doi.org/10.1002/(SICI)1097-0029(19990515/01)45:4/5<292::AID-JEMT13>3.3.CO;2-#

Van Laar AD, Jain S. Non-motor symptoms of Parkinson disease: update on the diagnosis and treatment. Neurologist 2004;10:185-94. DOI: https://doi.org/10.1097/01.nrl.0000131146.08278.a5

Goldman JG, Holden S. Treatment of psychosis and dementia in Parkinson’s disease. Curr Treat Options Neurol 2014;16:28. DOI: https://doi.org/10.1007/s11940-013-0281-2

Diaconu Ș, Falup-Pecurariu O, Țînț D, Falup-Pecurariu C. REM sleep behaviour disorder in Parkinson’s disease (review). Exp Ther Med 2021;22:812. DOI: https://doi.org/10.3892/etm.2021.10244

Pardo-Moreno T, García-Morales V, Suleiman-Martos S, et al. Current treatments and new, tentative therapies for Parkinson’s disease. Pharmaceutics 2023;15:770. DOI: https://doi.org/10.3390/pharmaceutics15030770

Magrinelli F, Picelli A, Tocco P, et al. Pathophysiology of motor dysfunction in Parkinson’s disease as the rationale for drug treatment and rehabilitation. Parkinsons Dis 2016;2016:9832839. DOI: https://doi.org/10.1155/2016/9832839

Nussbaum RL, Ellis CE. Alzheimer’s disease and Parkinson’s disease. N Engl J Med 2003;348:1356-64. DOI: https://doi.org/10.1056/NEJM2003ra020003

Chen RC, Chang SF, Su CL, et al. Prevalence, incidence, and mortality of PD: a door-to-door survey in Ilan county, Taiwan. Neurology 2001;57:1679-86. DOI: https://doi.org/10.1212/WNL.57.9.1679

Poewe W. Non-motor symptoms in Parkinson’s disease. Eur J Neurol 2008;15:14-20. DOI: https://doi.org/10.1111/j.1468-1331.2008.02056.x

Sorrentino ZA, Giasson BI. The emerging role of α-synuclein truncation in aggregation and disease. J Biol Chem 2020;295:10224-44. DOI: https://doi.org/10.1074/jbc.REV120.011743

Olanow CW. Levodopa/dopamine replacement strategies in Parkinson’s disease--future directions. Mov Disord 2008;23:S613-22. DOI: https://doi.org/10.1002/mds.22061

Mahlknecht P, Foltynie T, Limousin P, Poewe W. How does deep brain stimulation change the course of Parkinson’s disease? Mov Disord 2022;37:1581-92. DOI: https://doi.org/10.1002/mds.29052

Maguire CA, Ramirez SH, Merkel SF, et al. Gene therapy for the nervous system: challenges and new strategies. Neurotherapeutics 2014;11:817-39. DOI: https://doi.org/10.1007/s13311-014-0299-5

Prasuhn J, Davis RL, Kumar KR. Targeting mitochondrial impairment in Parkinson’s disease: challenges and opportunities. Front Cell Dev Biol 2021;8:615461. DOI: https://doi.org/10.3389/fcell.2020.615461

Smith JA, Das A, Ray SK, Banik NL. Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases. Brain Res Bull 2012;87:10-20. DOI: https://doi.org/10.1016/j.brainresbull.2011.10.004

Bostick JW, Schonhoff AM, Mazmanian SK. Gut microbiome-mediated regulation of neuroinflammation. Curr Opin Immunol 2022;76:102177. DOI: https://doi.org/10.1016/j.coi.2022.102177

Prime M, McKay JL, Bay A, et al. Differentiating Parkinson disease subtypes using clinical balance measures. J Neurol Phys Ther 2020;44:34-41. DOI: https://doi.org/10.1097/NPT.0000000000000297

Katzenschlager R, Lees AJ. Treatment of Parkinson’s disease: levodopa as the first choice. J Neurol 2002;249:II19-24. DOI: https://doi.org/10.1007/s00415-002-1204-4

Groiss SJ, Wojtecki L, Südmeyer M, Schnitzler A. Deep brain stimulation in Parkinson’s disease. Ther Adv Neurol Disord 2009;2:20-8. DOI: https://doi.org/10.1177/1756285609339382

Kim WS, Kågedal K, Halliday GM. Alpha-synuclein biology in Lewy body diseases. Alzheimers Res Ther 2014;6:73. DOI: https://doi.org/10.1186/s13195-014-0073-2

Aasly JO, Toft M, Fernandez-Mata I, et al. Clinical features of LRRK2-associated Parkinson’s disease in central Norway. Ann Neurol 2005;57:762-5. DOI: https://doi.org/10.1002/ana.20456

Tibar H, El Bayad K, Bouhouche A, et al. Non-motor symptoms of Parkinson’s disease and their impact on quality of life in a cohort of Moroccan patients. Front Neurol 2018;9:170. DOI: https://doi.org/10.3389/fneur.2018.00170

Qian L, Flood PM, Hong JS. Neuroinflammation is a key player in Parkinson’s disease and a prime target for therapy. J Neural Transm 2010;117:971-9. DOI: https://doi.org/10.1007/s00702-010-0428-1

Chao YX, Gulam MY, Chia NSJ, et al. Gut–brain axis: potential factors involved in the pathogenesis of Parkinson’s disease. Front Neurol 2020;11:849. DOI: https://doi.org/10.3389/fneur.2020.00849

Lindvall O, Kokaia Z. Prospects of stem cell therapy for replacing dopamine neurons in Parkinson’s disease. Trends Pharmacol Sci 2009;30:260-7. DOI: https://doi.org/10.1016/j.tips.2009.03.001

Heiss JD, Lungu C, Hammoud DA, et al. Trial of magnetic resonance-guided putaminal gene therapy for advanced Parkinson’s disease. Mov Disord 2019;34:1073-8. DOI: https://doi.org/10.1002/mds.27724

Mishima T, Fujioka S, Morishita T, et al. Personalized medicine in Parkinson’s disease: new options for advanced treatments. J Pers Med 2021;11:650. DOI: https://doi.org/10.3390/jpm11070650

Fearnley JM, Lees AJ. Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 1991;114:2283-301. DOI: https://doi.org/10.1093/brain/114.5.2283

Scheperjans F, Aho V, Pereira PAB, et al. Gut microbiota are related to Parkinson’s disease and clinical phenotype. Mov Disord 2015;30:350-8. DOI: https://doi.org/10.1002/mds.26069

Johnson S, Kantartjis M, Severson J, et al. Wearable sensor-based assessments for remotely screening early-stage Parkinson’s disease. Sensors 2024;24:5637. DOI: https://doi.org/10.3390/s24175637

Smith L, Schapira AHV. GBA Variants and Parkinson disease: mechanisms and treatments. Cells. 2022;11:1261. DOI: https://doi.org/10.3390/cells11081261

Fleming SM, Davis A, Simons E. Targeting alpha-synuclein via the immune system in Parkinson’s disease: current vaccine therapies. Neuropharmacology 2022;202:108870. DOI: https://doi.org/10.1016/j.neuropharm.2021.108870

Jing XZ, Yuan XZ, Luo X, et al. An update on nondopaminergic treatments for motor and non-motor symptoms of Parkinson’s disease. Curr Neuropharmacol 2023;21:1806-26. DOI: https://doi.org/10.2174/1570159X20666220222150811

Altham C, Zhang H, Pereira E. Machine learning for the detection and diagnosis of cognitive impairment in Parkinson’s disease: a systematic review. PLoS One 2024;19:e0303644. DOI: https://doi.org/10.1371/journal.pone.0303644

Ruggiero F, Lombi L, Molisso MT, et al. The impact of telemedicine on Parkinson’s care during the COVID-19 pandemic: an Italian online survey. Healthcare 2022;10:1065. DOI: https://doi.org/10.3390/healthcare10061065